Patent · US Active

Inhibiting CREB binding protein (CBP)

US12378242B2 · kind B2 · utility

0Cited by
9References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 10, 2022
Grant dateAug 5, 2025
Priority date
Expiry dateFeb 10, 2042

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.